Bayer is entering its annual general meeting with a tale of two narratives. On one side, the pharmaceuticals division is delivering tangible progress in both neurology and nephrology, while a state-of-the-art manufacturing facility in Leverkusen has just won industry recognition. On the other, the company is grappling with a net loss of €3.6 billion for 2025, a looming negative free cash flow of up to €2.5 billion for 2026, and net financial debts hovering near €30 billion. The contrast could hardly be starker.
Gene Therapy and Kidney Drug Advance
AskBio, Bayer’s gene therapy subsidiary, has filed an amendment with the FDA to supply its ongoing Phase II REGENERATE-PD study with material from the commercial manufacturing facility run by Viralgen, another group company. The trial is testing the experimental gene therapy Ametefgene parvec (AB-1005) in around 127 patients with mid-stage Parkinson’s disease across Germany, Poland, the UK, and the US. The goal is to slow disease progression and improve motor function. The FDA granted the candidate RMAT status in February 2025, and Japan followed with a comparable pioneering designation in December 2025.
Separately, Bayer reported positive Phase III data for its kidney drug Kerendia (finerenone). The FIND-CKD study — described by the company as the largest Phase III trial ever conducted in non-diabetic chronic kidney disease — showed that finerenone statistically significantly slowed the decline in kidney function compared to placebo. This marks the fifth completed Phase III study to deliver positive results for the drug. Bayer plans to submit the data to the FDA to expand the label to patients without diabetes, a move that would substantially broaden the addressable market.
Factory Innovation Wins an Award
While the pipeline grabs headlines, Bayer’s manufacturing arm is quietly racking up accolades. The International Society for Pharmaceutical Engineering has awarded the company’s new Supply Center SOLIDA-1 at the Leverkusen site. Built with an investment of around €275 million, it is the most digitally advanced production facility in the global Bayer network. According to the company, the integration of “Pharma 4.0” solutions means new drugs can reach the market up to a year earlier, allowing Bayer to make more efficient use of patent life and improve research returns.
Should investors sell immediately? Or is it worth buying Bayer?
The Stock: Technical Weakness and Analyst Optimism
The share price tells a more complicated story. After hitting a low in April 2025, the stock has nearly doubled to trade at around €40.55. But technical signals are flashing caution. On Wednesday afternoon, a “shooting star” candlestick pattern formed in XETRA trading — a formation often interpreted by chartists as a short-term sell signal. Short-term recovery attempts have fizzled quickly, and while the stock closed in positive territory on Wednesday, it remains well below its annual high. The relative strength index stands at 23, indicating a deeply oversold condition. On Thursday morning, the share price was virtually unchanged.
Despite the technical headwinds, analysts remain broadly constructive. The median price target is €46.85, implying roughly 17% upside from current levels. J.P. Morgan and Goldman Sachs have recently reiterated buy recommendations, and Deutsche Bank raised its target to €43 in mid-April. Consensus estimates for adjusted earnings per share in the current year stand at €4.25.
The Financial Squeeze and Key Dates
The operational progress comes against a backdrop of severe financial strain. Bayer expects a negative free cash flow of up to €2.5 billion in 2026, with around €5 billion earmarked for ongoing legal costs related to glyphosate litigation. The net financial debt stands at nearly €30 billion.
Two dates are now firmly on the radar for investors. On April 24, 2026, the virtual annual general meeting will vote on a proposal to keep the dividend at the statutory minimum of €0.11. Then on May 12, Bayer will release its first-quarter results for 2026, offering the first hard data on whether the efficiency gains from the new facilities and the restructuring under CEO Bill Anderson are translating into improved cash flow. The Q1 numbers will show whether the operational turnaround can keep pace with the share price recovery.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 23 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 23.
Bayer: Buy or sell? Read more here...
